Philips Healthcare parent company Royal Philips announced it has enrolled its first patient in the DEFINE GPS study (Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting).
The trial will investigate if guidance by instantaneous wave-free ratio (iFR) measurements co-registered on angiograms shows better outcomes and improves the cost-effectiveness of percutaneous coronary intervention procedures to open blocked coronary arteries. The study is estimated to include up to 3,200 patients across 100 sites and will be one of the largest studies ever sponsored by Philips, according to the vendor.
The study will evaluate iFR measurements paired with Philips' image-guided co-registration system, SyncVision, to boost peripheral component interconnect (PCI) guidance and provide better treatment outcomes. The trial is a follow-up to the DEFINE PCI study Philips conducted that evaluated the possibility of treating residual ischemia to improve clinical outcomes for coronary stent patients, it said.
